{"filing":{"accession_number":"0001437749-26-017809","cik":"0000832489","ticker":null,"company_name":"GeoVax Labs, Inc.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"govx20260519_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774926017809/govx20260519_8k.htm"},"classifications":[{"id":285,"accession_number":"0001437749-26-017809","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"GeoVax Labs entered into a securities purchase agreement on May 18, 2026 for an unregistered private placement of pre-funded warrants and common warrants to purchase up to 6,081,081 shares of common stock, raising approximately $2.7 million in net proceeds. The securities were issued under Section 4(a)(2) and Regulation D exemptions, and the filing explicitly notes the securities \"have not been registered under the Securities Act.\" This is a classic dilutive issuance—an unregistered equity offering that will substantially increase share count upon warrant exercise, materially affecting existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:41:18.723728+00:00","company_name":"GeoVax Labs, Inc.","ticker":null,"filing_date":"2026-05-19"},{"id":286,"accession_number":"0001437749-26-017809","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered sales of equity securities—specifically Pre-Funded Warrants and Common Warrants issued under Section 4(a)(2) and Rule 506(b) of Regulation D. This is a classic private placement of warrant instruments that will dilute existing shareholders upon exercise. The filing explicitly references warrant forms and future issuance of Common Warrant Shares, indicating a capital raise through dilutive equity instruments.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:41:18.723728+00:00","company_name":"GeoVax Labs, Inc.","ticker":null,"filing_date":"2026-05-19"},{"id":287,"accession_number":"0001437749-26-017809","item_number":"7.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The filing discloses pricing of an \"Offering\" via press release on May 18, 2026, filed under Item 7.01 (Regulation FD Disclosure). While the specific terms are not detailed in the excerpt, the reference to \"pricing of the Offering\" strongly suggests an equity or convertible securities issuance. The use of Item 7.01 rather than Item 3.02 (Unregistered Sales) is consistent with a registered offering, but the disclosure of pricing is material to investors assessing potential dilution and capital structure changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:41:18.723728+00:00","company_name":"GeoVax Labs, Inc.","ticker":null,"filing_date":"2026-05-19"}]}